377 related articles for article (PubMed ID: 23273339)
1. Exploring the reduction in myocardial infarctions in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel?
DiNicolantonio JJ; Serebruany VL
Int J Cardiol; 2013 May; 165(3):396-7. PubMed ID: 23273339
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
Husted S
Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
[TBL] [Abstract][Full Text] [Related]
3. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
[TBL] [Abstract][Full Text] [Related]
4. Lessons from platelet inhibition and patient outcomes.
Held C
Curr Opin Cardiol; 2012 Jul; 27(4):355-60. PubMed ID: 22565140
[TBL] [Abstract][Full Text] [Related]
5. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
Velders MA; Abtan J; Angiolillo DJ; Ardissino D; Harrington RA; Hellkamp A; Himmelmann A; Husted S; Katus HA; Meier B; Schulte PJ; Storey RF; Wallentin L; Gabriel Steg P; James SK;
Heart; 2016 Apr; 102(8):617-25. PubMed ID: 26848185
[TBL] [Abstract][Full Text] [Related]
7. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L
J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Guimarães PO; Tricoci P
Expert Opin Pharmacother; 2015; 16(13):1983-95. PubMed ID: 26224244
[TBL] [Abstract][Full Text] [Related]
9. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Shimada YJ; Bansilal S; Wiviott SD; Becker RC; Harrington RA; Himmelmann A; Neely B; Husted S; James SK; Katus HA; Lopes RD; Steg PG; Storey RF; Wallentin L; Cannon CP;
Am Heart J; 2016 Jul; 177():1-8. PubMed ID: 27297843
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST-segment elevation myocardial infarction.
Solomon MD; Go AS; Shilane D; Boothroyd DB; Leong TK; Kazi DS; Chang TI; Hlatky MA
J Am Coll Cardiol; 2014 Jun; 63(21):2249-57. PubMed ID: 24703914
[TBL] [Abstract][Full Text] [Related]
11. Angiographic and electrocardiographic parameters of myocardial reperfusion in angioplasty of patients with ST elevation acute myocardial infarction loaded with ticagrelor or clopidogrel (MICAMI-TICLO trial).
Winter JL; Lindefjeld DS; Veas N; Guarda E; Valdebenito M; Méndez M; Pérez O; Zuanic K; Mestas M; Martínez A
Cardiovasc Revasc Med; 2014; 15(5):284-8. PubMed ID: 25178668
[TBL] [Abstract][Full Text] [Related]
12. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Mahaffey KW; Held C; Wojdyla DM; James SK; Katus HA; Husted S; Steg PG; Cannon CP; Becker RC; Storey RF; Khurmi NS; Nicolau JC; Yu CM; Ardissino D; Budaj A; Morais J; Montgomery D; Himmelmann A; Harrington RA; Wallentin L;
J Am Coll Cardiol; 2014 Apr; 63(15):1493-9. PubMed ID: 24561148
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial.
Levin LÅ; Wallentin L; Bernfort L; Andersson D; Storey RF; Bergström G; Lamm CJ; Janzon M; Kaul P
Value Health; 2013 Jun; 16(4):574-80. PubMed ID: 23796291
[TBL] [Abstract][Full Text] [Related]
14. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
Varenhorst C; Alström U; Scirica BM; Hogue CW; Åsenblad N; Storey RF; Steg PG; Horrow J; Mahaffey KW; Becker RC; James S; Cannon CP; Brandrup-Wognsen G; Wallentin L; Held C
J Am Coll Cardiol; 2012 Oct; 60(17):1623-30. PubMed ID: 23021325
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
17. Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial.
DiNicolantonio JJ; Tomek A
Int J Cardiol; 2013 Oct; 168(4):4076-80. PubMed ID: 23911266
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
[TBL] [Abstract][Full Text] [Related]
19. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
Serebruany VL; DiNicolantonio JJ
Thromb Haemost; 2013 Jul; 110(1):5-10. PubMed ID: 23743577
[TBL] [Abstract][Full Text] [Related]
20. Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy.
Armstrong PW; Westerhout CM; Fu Y; Harrington RA; Storey RF; Katus H; James S; Wallentin L
Am J Med; 2013 Aug; 126(8):723-729.e1. PubMed ID: 23795897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
